Executive summary
According to McCall McPherson's clinic case series (via Dr. Amy Myers), GLP-1 receptor agonists reduced hsCRP within 72 hours to 1 week in some patients—well before the 2-2.5 month window needed for meaningful weight loss—suggesting a weight-loss-independent anti-inflammatory pathway that remains uncontrolled and hypothesis-generating. Dr. Siobhan Mitchell, MitoQ's Chief Science Officer (via Dr. Kara Fitzgerald), presented GDF-15, mitochondrial DNA copy number, and DunedinPACE as emerging mitochondrial-stress biomarkers, alongside company-affiliated MitoQ trial data requiring independent verification. At the Ehlers-Danlos Society's 2026 Female Health Summit, Shilpa Gowalla, PA-C (Mayo Clinic Florida) documented that hEDS/HSD diagnostic delay has grown from a historical 10-12 years to 22.1 years in a 2025 global survey of 3,906 patients, compounding a broader pattern of sex-based diagnostic bias in cardiac and pain care.
Key takeaways
- Add hsCRP monitoring to GLP-1 agonist protocols at baseline, 1 week, and 6 weeks—case data from McCall McPherson (via Dr. Amy Myers) show CRP reductions from 35 to 11 mg/L within 6 weeks independent of significant weight loss, though this remains uncontrolled, Grade D evidence.
- Apply sex-specific troponin cutoffs and heightened suspicion for atypical MI presentation in female patients—per Shilpa Gowalla's 2026 Female Health Summit talk, females present with chest pain in only 31% of MIs versus 42% of males, and sex-specific cutoffs double female MI detection rates.
- Screen for the hEDS/HSD-POTS-MCAS triad when hypermobility or dysautonomia symptoms cluster; Gowalla reports ~25% of hEDS/HSD patients meet criteria for all three, with a 2025 global survey (n=3,906) finding mean diagnostic delay has grown to 22.1 years.
- Treat MitoQ, CIRS reference-range adjustments (TGF-β1 cutoff of 5,000 per Ariana Becker/MoldCo), and GDF-15/mtDNA copy number as promising but company-affiliated or unvalidated biomarkers requiring independent primary-source verification before protocol adoption.
Key Clinical Takeaways
- **Consider hsCRP tracking in patients initiating GLP-1/GIP therapy**, even before meaningful weight loss occurs. According to McCall McPherson (via Dr. Amy Myers), case-level data showed CRP dropping from 35 to 11 mg/L over 6 weeks and from 11 to 3 mg/L after a single microdose injection in patients with minimal weight change—an uncontrolled but biologically plausible signal warranting monitoring, not yet a treatment indication. - **Add sex-specific troponin cutoffs and a lower threshold of clinical suspicion for atypical MI presentations in female patients.** Per Shilpa Gowalla's 2026 Female Health Summit presentation, females present with chest pain in only 31% of MIs versus 42% of males, and sex-specific troponin cutoffs have been shown to double acute MI detection rates in females. - **Screen for the POTS-MCAS-hEDS/HSD clinical triad** when hypermobility, dysautonomia, or mast cell symptoms cluster. Gowalla reports roughly 25% of hEDS/HSD patients meet criteria for all three conditions simultaneously, and a survey of predominantly female respondents found dysautonomia in 71.4%, POTS in >50%, and MCAS in 32%. - **Reassess TGF-β1 interpretation in CIRS work-ups.** Ariana Becker (MoldCo, via Dr. Amy Myers) argues the standard LabCorp reference range (~22,000) is clinically too permissive and recommends a cutoff closer to 5,000 for detecting biotoxin-related pathology—an unvalidated but practice-relevant heuristic from a commercially-affiliated source.
New Research & Biomarkers
Clinical Bottom Line: Uncontrolled clinic data suggest GLP-1/GIP receptor agonists (semaglutide, tirzepatide) may lower hsCRP within days, independent of adipose loss—but this remains Grade D, hypothesis-generating evidence. Study Design: According to McCall McPherson, speaking via Dr. Amy Myers, an unnamed thyroid-focused clinic tracked hsCRP quarterly across a self-selected cohort, then added ad hoc 1-week and 6-week draws after patients spontaneously reported inflammation improvement. No control group, randomization, or blinding was used. Key Findings: CRP fell from 35→11 mg/L over 6 weeks in one patient with an 8-year history of treatment-refractory elevated CRP; from 11→3 mg/L and ~6→<3 mg/L after single microdose injections in two additional cases, with only trivial weight change in all three. Clinical Application: McPherson frames CRP >3 mg/L as standard cardiovascular risk threshold and <1 mg/L as an optimal target; providers already prescribing GLP-1 agents might reasonably add hsCRP to existing labs, but should not extrapolate this to an autoimmune/inflammatory indication absent controlled trials. McPherson cites unspecified 'emerging research' on TNF-α, IL-1β, IL-6, and TGF-β1 modulation that requires independent literature verification before patient counseling. **Mitochondrial Stress Biomarkers as Early Aging-Risk Indicators** Clinical Bottom Line: GDF-15 and mitochondrial DNA (mtDNA) copy number are advancing as accessible functional biomarkers of mitochondrial stress that may precede conventional metabolic markers like A1C. Study Design: Dr. Siobhan Mitchell (MitoQ CSO, via Dr. Kara Fitzgerald's *New Frontiers in Functional Medicine*) synthesized observational cohort data, including the Dunedin Multidisciplinary Health and Development Study (n≈1000, now aged 50-55), which produced the DunedinPACE epigenetic aging clock. Key Findings: Per Mitchell, mitochondrial dysfunction repeatedly correlates with accelerated DunedinPACE scores, with inflammation trajectories predictive of mortality substantially driven by CD4+ T-cell and B-cell populations. GDF-15 elevation is associated with Alzheimer's disease, diabetes, depression, and fatigue severity, though it rises acutely with exercise—Mitchell cautions against post-HIIT testing to avoid false positives. mtDNA copy number in peripheral blood has been correlated with Alzheimer's disease, cardiovascular disease, and autoimmune conditions. Clinical Application: These markers are not yet standard functional medicine panel components; Mitchell notes GDF-15 is accessible via metabolomics-type panels. Interpret elevated GDF-15 in context of exercise timing, and treat isolated values cautiously—chronic non-resolution, not acute peaks, is the concerning pattern. **CIRS Biomarker Panel: A Contested Reference Range** Clinical Bottom Line: Ariana Becker's MoldCo (via Dr. Amy Myers) proposes several practice-pattern adjustments to the Shoemaker CIRS panel that diverge from standard lab reference ranges and require independent validation. Key Findings: MoldCo's unpublished internal data (self-described 'thousands' of samples) found 94% of CIRS patients had low/undetectable MSH (<8), 95% carried at least one susceptible HLA-DR haplotype (versus ~25% population prevalence), and 5% of CIRS cases occurred without any genetic susceptibility marker. VEGF patterns reportedly skew toward low values, diverging from Shoemaker's original one-third low/medium/high distribution. Clinical Application: These figures derive from a company selling the associated testing/treatment ($150-300/month), representing Grade D, conflict-of-interest-laden evidence; use as a hypothesis for further biomarker research, not a diagnostic override of validated lab reference ranges. **Sex-Based Diagnostic Disparities and hEDS/HSD Diagnostic Delay** Clinical Bottom Line: Diagnostic delay for hEDS/HSD is worsening, not improving, and independently predicts pain severity and disability. Study Design: Shilpa Gowalla's 2026 Ehlers-Danlos Society Female Health Summit talk synthesized multiple observational cohorts and cross-sectional surveys (Grade C-D, no RCTs). Key Findings: A 2025 global survey of 3,906 patients found mean diagnostic delay of 22.1 years (up from a historical 10-12 years), with patients reporting an average of 24 comorbid conditions; a German cohort found a 23-year delay. A multivariate analysis (89% female) identified diagnostic delay as one of three key variables predicting severe pain, with 43% of participants reporting severe pain and two-thirds reporting significant mobility disability. Separately, a 2022 guideline review found females waited a mean of 16 minutes longer than males for analgesia with equivalent abdominal pain scores, and a 2025 study found females with cardiac chest pain were half as likely as younger males to receive IV morphine. Clinical Application: Given the consistent directionality across independent datasets (ED wait times, opioid administration, MI presentation, diagnostic delay), providers should proactively screen female patients presenting with joint hypermobility, chronic fatigue, GI dysfunction, and dysautonomic symptoms for hEDS/HSD rather than defaulting to psychogenic attribution. **EDS Research Acceleration and Emerging Biomarker Development** Clinical Bottom Line: Connective tissue disorder research volume has surged, but mechanistic clarity on hEDS genetics remains unresolved, delaying targeted therapeutics. According to Gowalla (EDS Society Q&A), publication volume on connective tissue disorders over the past 5-6 years has exceeded the cumulative output of the prior 20 years, though the field still lacks consensus on whether hEDS is polygenic or attributable to a single causative mutation—the primary barrier to gene-therapy development. Mayo Clinic is reportedly beginning early exploratory work on fibronectin and collagen fragment biomarkers, with no sensitivity/specificity data yet available. A revised EDS diagnostic criteria update is anticipated in 2026.
Therapeutic Modalities & Protocols
Clinical Bottom Line: MitoQ demonstrates measurable improvements in mitochondrial membrane potential and vascular function in company-affiliated trials, though independent replication is needed before protocol adoption. Mechanism of Action: Per Dr. Siobhan Mitchell, MitoQ conjugates a ubiquinone (CoQ10-like) antioxidant to a triphenylphosphonium (TPP+) cation, achieving an estimated 90% mitochondrial delivery versus 5% for standard CoQ10, concentrating in the inner mitochondrial membrane to prevent lipid peroxidation. Dosage & Safety: Mitchell describes a tiered approach—10mg for general maintenance, 20mg as the standard trial dose (used in most cited studies), and 40mg for more advanced disease states. In older adults, 20mg over 6 weeks was associated with a reported 15% improvement in mitochondrial membrane potential and improved flow-mediated dilation; in postmenopausal women, 40mg over 4 weeks was associated with vascular function improvements of up to 50% toward premenopausal levels; in Type 2 diabetics, 40mg was associated with improved cardiac energy production. Clinical Pearls: Most trial data lack reported sample sizes, confidence intervals, or full citations in this interview format; treat as hypothesis-supporting pending primary-source verification given Mitchell's employment by the manufacturer. **Creatine and Citicoline for Cognitive/Mitochondrial Support** Clinical Bottom Line: Creatine's ergogenic evidence base is strong for muscle (Grade B) but weaker for brain applications due to limited blood-brain barrier penetration. Mechanism: Creatine buffers ATP regeneration via phosphocreatine independent of oxidative phosphorylation. Per Mitchell, oral citicoline at 500mg increased brain phosphocreatine reserves in an unspecified clinical study, offering a brain-targeted alternative. Glycine, the rate-limiting endogenous creatine precursor, requires adequate methyl donor status (B12, folate, SAMe) for the terminal synthesis step. Clinical Pearls: A single-study finding cited by Mitchell showed nicotinamide riboside outperformed high-intensity interval exercise in improving muscle-specific epigenetic age—a counterintuitive result requiring replication before altering exercise prescriptions. **S-Equol for Perimenopausal/Postmenopausal Support** Clinical Bottom Line: S-equol, a gut-bacteria-derived daidzein metabolite produced by an estimated 50% of Asian women versus 20% of Western women/men (per Mitchell), preferentially activates estrogen receptor beta, offering theoretical metabolic benefit with lower proliferative signaling than ERα-dominant phytoestrogens. Clinical Application: Cited (uncited-study) outcomes include reduced arterial stiffness, reduced vasomotor symptoms, and reduced visceral adiposity in equol-producers given supplemental S-equol. Observational data associate endogenous equol production with reduced reproductive cancer incidence via a preclinical (in vitro only) tumor-suppressor reactivation mechanism—this should not be presented to patients as established chemoprevention. **Pediatric Root-Cause Infection/Inflammation Protocol (RESET Framework)** Clinical Bottom Line: In a specialty pediatric referral population, Dr. Somer DelSignore reports that only 1 in 25 patients present with a single isolated diagnosis, with tick-borne triple co-infection (Borrelia, Babesia, Bartonella) in an estimated 25-30% of infection-suspected cases—Grade D, non-generalizable clinic data from a highly selected referral population. Protocol: DelSignore's RESET sequence (Reduce inflammation, Eliminate toxins, Support gut, Eradicate infection, Transform health) delays dietary restriction until roughly the third visit (~12 weeks) to build treatment buy-in, using weekly single-food substitution rather than abrupt elimination. She recommends broader pediatric MTHFR screening and glutathione as a first-line supplement for cumulative toxic burden, disclosing a commercial affiliation with Wholesome Root Nutraceuticals. **Mast Cell Stabilization for Cold Urticaria/Histamine Intolerance** Clinical Bottom Line: In pediatric cold urticaria with suspected MCAS, EpiPen and H1/H2 blockade (diphenhydramine/famotidine) remain mandatory rescue therapy; natural mast cell stabilizers are adjunctive only. Per Dr. Will Cole's panel, adjunctive options discussed include quercetin (dose unspecified, described as requiring higher therapeutic doses), stinging nettle, vitamin C, DAO enzyme supplementation, and luteolin, alongside a low-histamine diet using short-cook (4-6 hour) bone broth to limit histamine accumulation. No dosing, effect sizes, or controlled data were provided—Grade D, single-case discussion with commercial supplement conflict of interest. **Metabolic/Nutraceutical Approaches to Early Cataract Change** Clinical Bottom Line: Early lens glycation changes are mechanistically plausible targets for glycemic optimization, but no human trial data support reversal claims. Per Dr. Eric Berg, proposed adjuncts include fructose elimination, intermittent fasting to promote autophagy, nutritional ketosis, zinc, dietary carnosine, lutein/zeaxanthin, and topical N-acetyl carnosine (distinct from N-acetylcysteine) eye drops—supported only by veterinary/consumer references, not human RCTs. Fasting protocols require caution in insulin-dependent diabetics and patients on sulfonylureas given hypoglycemia risk. **Integrative Wart Management** Clinical Bottom Line: Topical salicylic acid retains the strongest evidence base among options discussed for verruca vulgaris. Dr. Will Cole's panel cited an unreferenced ~70% improvement figure for salicylic acid, directionally consistent with published dermatologic cure rates of 60-75%. Adjuncts discussed (tea tree oil/garlic, propolis, manuka honey, zinc glycinate, systemic antivirals) lack controlled data; prior 10-day homeopathic trials were deemed too short to assess efficacy. **Topical Olive Oil for Skin Barrier and Hair Cosmesis** Clinical Bottom Line: Olive oil is a biologically plausible, low-cost occlusive emollient but lacks comparative efficacy data versus ceramide-based or hyaluronic acid moisturizers. Dr. Amy Kassouf (Cleveland Clinic) recommends applying while skin is damp post-shower to trap moisture, patch-testing first, avoiding scalp application in acne/seborrheic-prone patients, and pairing with separate sunscreen since removing surface flaking can paradoxically increase UV penetration. **Antihypertensive Risk Perception and Lifestyle-First Sequencing** Clinical Bottom Line: One physician's unreferenced Grade D opinion flags amlodipine (edema), labetalol (fatigue/CKD association), hydralazine (precipitous BP drops), clonidine (sedation), and HCTZ (hypokalemia/hypomagnesemia risk, especially >65) as agents warranting closer monitoring—but this omits landmark outcome trials (ALLHAT, SPRINT) supporting thiazides as first-line, evidence-proven therapy. Per this source (via Dr. Suneel Dhand), the speaker recommends lisinopril or low-dose metoprolol/atenolol as preferred first-line agents alongside a parallel '30-day blood pressure reset' lifestyle program, disclosed as a commercial product. **N-of-1 Biohacking Modalities (Mark Hyman)** Clinical Bottom Line: Dr. Mark Hyman's self-reported recovery from six spine surgeries and prior mercury-related chronic fatigue illustrates several actionable clinical pearls despite Grade D, single-subject, commercially-conflicted evidence. Key pearls: mandatory G6PD screening before high-dose IV vitamin C to prevent hemolysis; distinguishing physiologic depression (from hypothyroidism, low testosterone, anemia, systemic inflammation) from primary psychiatric depression in post-surgical patients; caution that metformin's mitochondrial complex I inhibition may blunt resistance-training hypertrophy, relevant when considering off-label longevity use in patients prioritizing muscle mass; and avoiding cold-water immersion within ~4 hours after resistance training to preserve anabolic signaling. Peptides (thymosin alpha-1, BPC-157) and stem cell/exosome therapies remain experimental, with primarily animal-model data and meaningful contamination risk in non-reputable sourcing. **Diet-First Weight Loss Framing (JD Vance Case)** Clinical Bottom Line: A self-reported, unverified ~20 lb weight loss and 40% relative visceral fat reduction via high-protein, low-carbohydrate, sugar-elimination diet (per commentary from Dr. Ben and Dr. Sunil, via Dr. Suneel Dhand) illustrates standard diet-first counseling principles but provides no validated effect size data. Clinical Application: Useful as patient-communication material—reframing 'diet' as identity-based lifestyle change, screening for hidden sugar sources, and reinforcing that exercise alone is insufficient without caloric/carbohydrate modification—but the specific figures cited (20 lb, 40% visceral fat) are unverified self-report and should not be quoted as evidence.
Practice Implementation & Pearls
According to Mayo Clinic's 'Key into Quality' podcast (Erin Fairchild, Senior Patient Advisor), replacing generic comment boxes with two targeted prompts—'What impressed you?' and 'What disappointed you?'—generated approximately 360,000 categorized patient/family comments over 15 months, using NLP (Qualtrics XM Discover) mapped to organizational values. Practices without NLP licensing can replicate this at smaller scale via manual spreadsheet curation, per Kelly Vorseth (Director, Patient Experience). Clinical pearl: filter comments for actionability before dissemination to unit leaders (e.g., parking complaints generate low value for unit-level action), and diversify featured narratives across nursing, physician, and support staff roles to avoid reinforcing individual-hero framing over collective culture. **Pacing Frameworks for Chronically Ill Patients and Caregivers** Two EDS Society Summit speakers offered complementary, non-pharmacologic pacing tools. Shilpa Gowalla's 'kumquats' heuristic breaks activity into small increments, with the rule that any task requiring multi-hour recovery should be reduced in duration until a sustainable threshold is found. Separately, Sarah Hamilton's 'one-minute rule' pairs low-effort tasks with fixed passive-wait intervals (kettle boiling, toast toasting) rather than tying activity to subjective energy levels—both are zero-cost, patient-education-appropriate tools for EDS, POTS, and ME/CFS-adjacent fatigue management, though neither has been validated against formal pacing/PEM outcome measures. **Patient Communication for Diagnostic Delay and Validation** Across both EDS Society talks, the single most patient-endorsed request identified in a cross-sectional study of 2,125 US adults with hEDS/HSD was for clinicians to demonstrate more disease-specific knowledge. Practical application: proactively naming hEDS/HSD, POTS, and MCAS in differential discussions—even before formal diagnosis—can itself reduce perceived dismissal and improve therapeutic alliance, per Gowalla. Preparing a short, prioritized 3-item list per visit and bringing a support person are recommended patient-facing strategies given typical visit-time constraints.
Sources
- Dr. Amy Myers (McCall McPherson interview)
- Dr. Kara Fitzgerald, FxMed, Longevity & Epigenetics (Dr. Siobhan Mitchell/MitoQ interview)
- The Ehlers-Danlos Society, 2026 Female Health Summit (Shilpa Gowalla, PA-C)
- The Ehlers-Danlos Society, Female Health Summit Q&A
- The Ehlers-Danlos Society, 2026 Female Health Summit (Sarah Hamilton)
- Dr. Jill Carnahan, Resiliency Radio (Dr. Somer DelSignore)
- Dr. Amy Myers (Ariana Thacker/Becker, MoldCo interview)
- Dr. Eric Berg, DC
- Dr. Will Cole (cold urticaria episode)
- Dr. Will Cole (wart-like bumps episode)
- Mark Hyman, MD
- Dr. Suneel Dhand (JD Vance weight loss episode)
- Dr. Suneel Dhand (blood pressure medications episode)
- Mayo Clinic, 'Key into Quality' podcast
- Cleveland Clinic, Health Essentials podcast (Dr. Amy Kassouf)